Since publication of the EMPA-REG trial, two important questions have been gaining ground: first, whether the protective effect of SGLT2 on heart failure is a class-level effect [38, 39]; and second, speculation as to the possible underlying mechanism. The gene discussed is SLC5A2; the disease is heart failure.